Marimed (MRMD) Preferred Stock Liabilities (2020 - 2026)
Marimed (MRMD) posted quarterly Preferred Stock Liabilities of $6.9 million for Q1 2026, down 52.92% year-over-year from $14.7 million in Q1 2025, and down 52.92% quarter-over-quarter from $14.7 million in Q4 2025.
Marimed (MRMD) Preferred Stock Liabilities (2020 - 2026) Analysis & Trends
Marimed (MRMD) has reported Preferred Stock Liabilities for 7 consecutive years, with $6.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Preferred Stock Liabilities fell 52.92% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (down 52.92% YoY), while the FY2025 annual figure was $14.7 million, down 22.5% from the prior year.
- Preferred Stock Liabilities eased to $6.9 million in Q1 2026 per MRMD's latest filing, from $14.7 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $37.7 million in Q1 2022 and bottomed at $6.9 million in Q1 2026.
- Historically, Preferred Stock Liabilities has averaged $23.0 million across 5 years, with a median of $19.0 million in 2023.
- Annual changes were most pronounced in 2022 — Preferred Stock Liabilities changed 0.0% — and 2026, when it tumbled 52.92%.
- Marimed's Preferred Stock Liabilities stood at $37.7 million in 2022, then tumbled by 49.64% to $19.0 million in 2023, then changed by 0.0% to $19.0 million in 2024, then declined by 22.5% to $14.7 million in 2025, then slumped by 52.92% to $6.9 million in 2026.
- Business Quant data shows MRMD's Preferred Stock Liabilities at $6.9 million in Q1 2026, $14.7 million in Q4 2025, and $14.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Marimed | 27.77 Mn | 19.33 Mn | 16.23 Mn | 6.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.93 Mn |
| Mar 31, 2026 | 6.93 Mn |
| Dec 31, 2025 | 14.73 Mn |
| Sep 30, 2025 | 14.73 Mn |
| Jun 30, 2025 | 14.73 Mn |
| Mar 31, 2025 | 14.73 Mn |
| Dec 31, 2024 | 19.00 Mn |
| Sep 30, 2024 | 19.00 Mn |
| Jun 30, 2024 | 19.00 Mn |
| Mar 31, 2024 | 19.00 Mn |
| Dec 31, 2023 | 19.00 Mn |
| Sep 30, 2023 | 19.00 Mn |
| Jun 30, 2023 | 21.90 Mn |
| Mar 31, 2023 | 37.73 Mn |
| Dec 31, 2022 | 37.73 Mn |
| Sep 30, 2022 | 37.73 Mn |
| Jun 30, 2022 | 37.73 Mn |
| Mar 31, 2022 | 37.73 Mn |
| Dec 31, 2021 | 37.73 Mn |
| Sep 30, 2021 | 37.73 Mn |